How Does Histology Help Differentiate MDS-EB from Other Hematological Disorders?
Differentiating MDS-EB from other hematological malignancies, such as acute myeloid leukemia (AML) and other subtypes of MDS, relies heavily on histological assessment. MDS-EB is characterized by a blast count less than 20%, distinguishing it from AML. Moreover, specific dysplastic changes in MDS-EB are not typically seen in other conditions, aiding in accurate diagnosis.
